Nothing Special   »   [go: up one dir, main page]

WO2021004229A1 - Nouvelle application de l'inhibiteur du récepteur de chimiokine ccr6 dans la prévention de la récurrence du psoriasis - Google Patents

Nouvelle application de l'inhibiteur du récepteur de chimiokine ccr6 dans la prévention de la récurrence du psoriasis Download PDF

Info

Publication number
WO2021004229A1
WO2021004229A1 PCT/CN2020/095956 CN2020095956W WO2021004229A1 WO 2021004229 A1 WO2021004229 A1 WO 2021004229A1 CN 2020095956 W CN2020095956 W CN 2020095956W WO 2021004229 A1 WO2021004229 A1 WO 2021004229A1
Authority
WO
WIPO (PCT)
Prior art keywords
psoriasis
pharmaceutical composition
recurrence
cells
ccr6
Prior art date
Application number
PCT/CN2020/095956
Other languages
English (en)
Chinese (zh)
Inventor
郑捷
刘娜
覃慧
李霞
薛峰
陈利红
王岚琦
权晟
张莉
Original Assignee
上海交通大学医学院附属瑞金医院
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 上海交通大学医学院附属瑞金医院 filed Critical 上海交通大学医学院附属瑞金医院
Priority to EP20837486.8A priority Critical patent/EP4026561A4/fr
Priority to US17/775,618 priority patent/US20220401459A1/en
Publication of WO2021004229A1 publication Critical patent/WO2021004229A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/205—Scaling palpular diseases, e.g. psoriasis, pytiriasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Definitions

  • the invention relates to the field of biomedicine, in particular to the new application of chemokine receptor CCR6 inhibitors in preventing the recurrence of psoriasis.
  • Psoriasis is a typical of common inflammatory skin diseases, with an incidence of about 2%-3% worldwide, and recurrence is its characteristic. Plaque type is the most common type of psoriasis, accounting for about 90% of all psoriasis patients. It is manifested as papules and scaly erythema with clear boundaries, often symmetrically distributed on the scalp, limbs, and trunk.
  • the pathogenesis of psoriasis is currently unclear. Genetic susceptibility, environmental triggers, skin barrier function destruction and immune system dysfunction are all involved, and different cells participate in different stages of disease occurrence, development, stability, and recurrence.
  • the classic treatment methods for psoriasis include mild to moderate topical medications such as emollients, glucocorticoids, vitamin D derivatives, and moderate to severe systemic treatments such as phototherapy, methotrexate, cyclosporine, and albino Dimension A.
  • the main immunological event in psoriasis is the activation of skin keratinocytes by inflammatory factors such as TNF-a, IL-23 and IL17. It has been reported that the key pathogenic product of psoriasis is IL-17. As a result, methods for targeted treatment of psoriasis for cytokines have emerged.
  • biologics are a major innovation in the treatment of psoriasis, a considerable number of patients use biologics to achieve remission in the initial stage, and gradually lose their efficacy as the treatment time increases, leading to recurrence of the disease, and some even progress to more serious silver.
  • Types of soria such as pustular, erythroderma and joint psoriasis.
  • topical glucocorticoids have the longest history and are the most widely used. Both physicians and patients are more troubled by their recurrence after stopping the drug and the recurrence and aggravation during their continued use.
  • the purpose of the present invention is to provide a therapy for preventing the recurrence of psoriasis during the treatment of psoriasis.
  • chemokine receptor CCR6 inhibitor for preparing a preparation or composition, which is administered to a subject to prevent Recurrence of psoriasis.
  • the subject is a mammal.
  • the mammals include human or non-human mammals.
  • the non-human mammals include rodents (such as rats and mice) and primates (such as monkeys).
  • the subject is a patient with psoriasis.
  • the subject is a patient who has experienced recurrence of psoriasis.
  • the chemokine receptor CCR6 inhibitor includes: extracellular soluble fragments of CCR6, blocking antibodies, small molecule compounds, antisense nucleic acids, or combinations thereof.
  • a pharmaceutical product for preventing the recurrence of psoriasis including:
  • a first pharmaceutical composition comprising (a1) a chemokine receptor CCR6 inhibitor, and (a2) a first pharmaceutically acceptable carrier;
  • a second pharmaceutical composition comprising (b1) other drugs or active ingredients that can be used to treat psoriasis other than CCR6 inhibitors, and (b2) a second pharmaceutically acceptable Accepted carrier.
  • the (b1) other drugs or active ingredients that can be used to treat psoriasis other than CCR6 inhibitors include: glucocorticoids, including IL-17A antagonists, TNF-a antagonists Agents, IL-12/IL-23 antagonists, calcineurin inhibitors, vitamin D3 derivatives, or combinations thereof.
  • component (a1) accounts for 0.01-99.99 wt% of the total weight of the first pharmaceutical composition, preferably 0.1-90 wt%, more preferably 1 -80wt%.
  • the concentration of component (a1) is 10 mg/ml-1000 mg/ml, preferably 20-500 mg/ml, more preferably 50-200 mg/ml.
  • component (b1) accounts for 0.01-99.99 wt% of the total weight of the second pharmaceutical composition, preferably 0.1-90 wt%, more preferably 1 -80wt%.
  • (b1) is a glucocorticoid, and (b1) accounts for 0.01-50 wt% of the total weight of the second pharmaceutical composition, preferably 0.01-10wt%, more preferably 0.1-5wt%.
  • the (b1) in the second pharmaceutical composition, is an IL-17A antagonist, and the concentration of (b1) in the second pharmaceutical composition is 1-1000 mg/ml , Preferably 5-500mg/ml, more preferably 10-100mg/ml.
  • the first pharmaceutical composition is liquid, solid, or semi-solid.
  • the dosage form of the first pharmaceutical composition is an oral dosage form, an injection, or an external pharmaceutical dosage form.
  • the dosage form of the first pharmaceutical composition includes a tablet, a granule, a capsule, an oral liquid, or an injection.
  • the first pharmaceutical composition is an oral preparation.
  • the carrier is selected from the following group: infusion carrier and/or injection carrier, preferably, the carrier is one or more carriers selected from the group: physiological saline, glucose Salt water, or a combination thereof.
  • the second pharmaceutical composition is liquid, solid, or semi-solid.
  • the dosage form of the second pharmaceutical composition is an oral dosage form, an injection, or a topical pharmaceutical dosage form.
  • the second pharmaceutical composition is an external pharmaceutical dosage form.
  • the dosage form of the second pharmaceutical composition includes a tablet, a granule, a capsule, an oral liquid, or an injection.
  • the second pharmaceutical composition is an oral preparation.
  • first pharmaceutical composition and the second pharmaceutical composition in the pharmaceutical product can be made into the same dosage form or different dosage forms.
  • first pharmaceutical composition and the second pharmaceutical composition in the pharmaceutical product can be administered to the subject simultaneously or sequentially.
  • a pharmaceutical product including:
  • a first container and a first pharmaceutical composition in the first container, the first pharmaceutical composition comprising (a1) a chemokine receptor CCR6 inhibitor, and (a2) a first pharmaceutically acceptable Accepted vehicle;
  • a second container and a detection agent in the second container for detecting a substance selected from the group consisting of IL-17, ⁇ T17 cells, CD3 + T cells, CCL20 in a sample derived from a subject , CCR6, and combinations thereof.
  • the sample includes: blood, skin tissue, drainage and distal lymph node tissue or a combination thereof.
  • the detection includes qualitative detection and quantitative detection.
  • the pharmaceutical product further includes an instruction, and the instruction records:
  • the normal value refers to a value measured in a normal individual.
  • the normal individual refers to an individual who does not suffer from psoriasis, or an individual who has not relapsed after psoriasis treatment.
  • a method for preventing the recurrence of psoriasis is provided by administering the pharmaceutical product as described in the third or fourth aspect of the present invention to a desired subject.
  • Figure 1 shows the three time points before and after halometasone treatment and the recurrence of psoriasis: flow cytometry showed that the proportion of IL-17 producing cells in peripheral blood increased after treatment and decreased when recurrence; skin lesions IL-17 produced T cells The proportion of (T17 cells) decreased after treatment and increased when recurrence; transcriptome sequencing (RNA-seq) showed that the expression of many genes in the skin lesions of patients with psoriasis changed, especially chemokines such as CCL20, CCL5, CCL2 CXCL10 decreased after treatment and increased when recurring.
  • chemokines such as CCL20, CCL5, CCL2 CXCL10 decreased after treatment and increased when recurring.
  • Figure 2 shows that in mice treated with halometasone topical treatment of ear skin inflammation, the symptoms of skin psoriasis were significantly alleviated, but the proportion of ⁇ T17 cells in the drainage and distal lymph nodes was significantly increased.
  • Figure 3 shows that when psoriasis is induced again, mice treated with halometasone quickly relapsed, and the proportion of ⁇ T17 cells in the drainage and distal lymph nodes decreased significantly.
  • Figure 4 shows the simultaneous treatment of wild-type (WT) and CCR6 -/- mice with GC. Compared with WT mice, CCR6 -/- mice not only showed reduced psoriasis symptoms, but also did not increase the proportion of ⁇ T cells in lymph nodes after halometasone treatment.
  • Figure 5 shows that halometasone can quickly and effectively control psoriasis, but the disease is easy to relapse. After treatment, the expression of psoriasis-related genes decreases, and the expression is up-regulated when recurrence.
  • Figure 6 shows that the proportion of distal lymph node ⁇ T and its subgroups V ⁇ 4 and V ⁇ 4V ⁇ 4 T cells and the proportion of IL-17 secreted after stimulation are higher after halometasone treatment.
  • Figure 7 shows that the proportion of ⁇ T17 cells in the lymph nodes of mice in the halometasone treatment group is still significantly increased after withdrawal.
  • Figure 8 shows that the proportion of ⁇ T17 cells in the lymph nodes of the halometasone-treated group mice is still significantly increased after stimulation.
  • Figure 9 shows that psoriasis was induced again.
  • the proportion of V ⁇ 4 and V ⁇ 4V ⁇ 4 T cells in the skin was higher in the GC group, but there was mild or no change in the lymph nodes.
  • Figure 10 shows that when psoriasis recurred after GC treatment, compared with wild-type mice, CCR6ko mice still showed milder psoriasis symptoms, and there was no decrease in the proportion of ⁇ T17 cells in the lymph nodes of the GC group.
  • Figure 11 shows that the use of FTY720 makes ⁇ T17 cells no longer migrate from the draining lymph nodes, and the mice in the GC group no longer have rapid recurrence of psoriasis.
  • Figure 12 shows whether the imiquimod that induces the recurrence of psoriasis is replaced with mannan, and the mice in the GC group no longer have rapid disease recurrence.
  • the present inventors used the mouse psoriasis model induced by imiquimod (IMQ) to simulate the whole process of external use of glucocorticoids for psoriasis patients to treat the disease-withdrawal-disease recurrence.
  • IMQ mouse psoriasis model induced by imiquimod
  • GC mouse psoriasis model induced by imiquimod
  • mice previously treated with GC showed more severe disease recurrence, including faster epidermal thickening and more infiltration of neutrophils.
  • the proportion of ⁇ T17 cells in the drainage and distant lymph nodes was no different or even lower than that of the control.
  • mice with CCR6 gene knockout did not affect the redistribution of ⁇ T17 cells in the body and thus did not lead to recurrence of psoriasis. Further research found that this type of ⁇ T17 cells with migration ability have memory cell properties. In summary, the inventors found that inhibiting the redistribution of ⁇ T17 cells has a key role in controlling the recurrence of skin inflammation.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an effective amount of the following active ingredients: chemokine receptor CCR6 inhibitor and other drugs for treating psoriasis or their active ingredients.
  • an effective amount or “effective dose” refers to an amount that can produce function or activity on humans and/or animals and can be accepted by humans and/or animals.
  • pharmaceutically acceptable ingredients are substances that are suitable for humans and/or mammals without excessive adverse reactions (such as toxicity, irritation, and allergic reactions), that is, substances with a reasonable benefit/risk ratio.
  • pharmaceutically acceptable carrier refers to a carrier for the administration of a therapeutic agent, including various excipients and diluents.
  • the pharmaceutical composition of the present invention contains a safe and effective amount of the active ingredient of the present invention and a pharmaceutically acceptable carrier.
  • a pharmaceutically acceptable carrier include (but are not limited to): saline, buffer, glucose, water, glycerol, ethanol, and combinations thereof.
  • the pharmaceutical preparation should match the mode of administration, and the dosage form of the pharmaceutical composition of the present invention is an injection.
  • it can be prepared by conventional methods with physiological saline or an aqueous solution containing glucose and other adjuvants.
  • the pharmaceutical composition should be manufactured under aseptic conditions.
  • the effective amount of the active ingredient of the present invention can vary with the mode of administration and the severity of the disease to be treated.
  • the selection of the preferred effective amount can be determined by a person of ordinary skill in the art based on various factors (for example, through clinical trials).
  • the factors include, but are not limited to: the pharmacokinetic parameters of the active ingredients such as bioavailability, metabolism, half-life, etc.; the severity of the disease to be treated by the patient, the patient's weight, the patient's immune status, and administration Way etc. For example, due to the urgent need to treat the condition, several divided doses can be given every day, or the dose can be reduced proportionally.
  • the pharmaceutically acceptable carriers of the present invention include (but are not limited to): water, saline, liposomes, lipids, proteins, protein-antibody conjugates, peptides, cellulose, nanogels, or Its combination.
  • the choice of carrier should match the mode of administration, which are well known to those of ordinary skill in the art.
  • the first active ingredient (a1) chemokine receptor CCR6 inhibitor provided by the present invention can be combined with the second active ingredient (b1) other than CCR6 inhibitors that can be used to treat psoriasis or its active ingredients Drug combination.
  • the second active ingredient (b1) is an anti-epileptic drug that is already available in the prior art, including but not limited to: glucocorticoids, including IL-17A antagonists, TNF-a antagonists, IL-12/ IL-23 antagonist, calcineurin inhibitor, vitamin D3 derivative, or a combination thereof.
  • the present invention specifically addresses the recurrence of psoriasis.
  • the present invention aims at the redistribution characteristics of pathogenic cells during the recurrence of psoriasis, which is better than general treatment control drugs.
  • the present invention can effectively inhibit the redistribution of pathogenic cells, thereby effectively preventing or alleviating the recurrence of psoriasis.
  • Example 1 Detection of changes in the expression of related genes in patients with recurrent psoriasis
  • GC glucocorticoid
  • RNA-seq transcriptome sequencing
  • Example 2 Detection of changes in T cell distribution in patients with relapsed psoriasis
  • Example 3 Detecting changes in T cell distribution in an animal model of psoriasis treated by GC
  • IMQ IMQ to smear all mice for three weeks. Among them, from the 6th day, GC or Vaseline (Vas) was applied to the skin of the mice, and all treatments were stopped on the 21st day. The mice entered a two-week drug withdrawal period, and then applied IMQ again for 7 consecutive days to induce psoriasis recurrence.
  • GC or Vaseline Vas
  • Example 4 Detection of IL-17 secretion level changes in animal models of psoriasis treated by GC
  • ⁇ T cells are the main cells secreting IL-17 in the skin.
  • ⁇ T17 cells in the skin and lymph nodes were detected.
  • ⁇ T17 cells in the skin may migrate to drainage and distant lymph nodes after GC treatment, and have a memory cell phenotype.
  • Example 5 Detection of changes in ⁇ T17 cell levels and IL-17 secretion levels in mice during the withdrawal period
  • mice in the experimental group and the control group rested for 2 weeks.
  • Example 6 Detection of ⁇ T17 cell level and IL-17 secretion level in a mouse model of psoriasis recurrence
  • IMQ was applied again to the experimental group and the control group mice to simulate the recurrence of psoriasis after clinical withdrawal.
  • Example 7 Study on the relationship between CCR6 gene knockout and ⁇ T17 cell redistribution
  • cytokine receptors CCR6 and CCR2 mediate the migration of ⁇ T17 cells in the occurrence of skin inflammation.
  • wild-type mice (WT), CCR6 -/- and CCR2 -/- mice were used to study the above-mentioned mechanism.
  • CCR6 gene knockout will inhibit the migration of ⁇ T17 from the skin to the lymph nodes, and it can also inhibit its migration from the lymph nodes to the skin.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)

Abstract

L'invention concerne une nouvelle application d'un inhibiteur du récepteur de chimiokine CCR6 dans la prévention de la récurrence du psoriasis. De façon spécifique, l'invention concerne une utilisation de l'inhibiteur du récepteur de chimiokine CCR6 pour préparer une préparation ou une composition qui est administrée à un sujet de façon à empêcher la récurrence du psoriasis chez celui-ci. L'invention concerne également un produit pharmaceutique qui empêche la récurrence du psoriasis. L'utilisation des produits médicamenteux de l'invention peut prévenir ou atténuer efficacement la récurrence du psoriasis.
PCT/CN2020/095956 2019-07-08 2020-06-12 Nouvelle application de l'inhibiteur du récepteur de chimiokine ccr6 dans la prévention de la récurrence du psoriasis WO2021004229A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP20837486.8A EP4026561A4 (fr) 2019-07-08 2020-06-12 Nouvelle application de l'inhibiteur du récepteur de chimiokine ccr6 dans la prévention de la récurrence du psoriasis
US17/775,618 US20220401459A1 (en) 2019-07-08 2020-06-12 New application of chemokine receptor ccr6 inhibitor in preventing recurrence of psoriasis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910612157.2 2019-07-08
CN201910612157.2A CN112190708B (zh) 2019-07-08 2019-07-08 趋化因子受体ccr6抑制剂在预防银屑病复发中的新应用

Publications (1)

Publication Number Publication Date
WO2021004229A1 true WO2021004229A1 (fr) 2021-01-14

Family

ID=74004523

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/095956 WO2021004229A1 (fr) 2019-07-08 2020-06-12 Nouvelle application de l'inhibiteur du récepteur de chimiokine ccr6 dans la prévention de la récurrence du psoriasis

Country Status (4)

Country Link
US (1) US20220401459A1 (fr)
EP (1) EP4026561A4 (fr)
CN (2) CN112190708B (fr)
WO (1) WO2021004229A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4223289A1 (fr) * 2022-02-07 2023-08-09 Liangdan Sun Application de préparation pour inhiber l'expression camk2g dans la préparation d'un médicament pour le traitement du psoriasis

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002026764A2 (fr) * 2000-09-26 2002-04-04 Genaissance Pharmaceuticals, Inc. Haplotypes du gene ccr6
CN103588697A (zh) * 2012-08-14 2014-02-19 中国科学院上海药物研究所 一类2，5-二取代苯磺酰胺类化合物及其制备方法和用途
WO2015084842A1 (fr) * 2013-12-02 2015-06-11 Chemocentryx, Inc. Composés ccr6
WO2017087607A1 (fr) * 2015-11-19 2017-05-26 Chemocentryx, Inc. Modulateurs des récepteurs des chimiokines
WO2019136370A2 (fr) * 2018-01-08 2019-07-11 Chemocentryx, Inc. Méthodes de traitement du psoriasis pustuleux généralisé avec un antagoniste de ccr6 ou cxcr2

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005095953A2 (fr) * 2004-03-04 2005-10-13 Bayer Healthcare Ag Agents diagnostiques et therapeutiques destines a des maladies associees au recepteur de chimiokine c-c de type 6 (ccr6)
JP2008530137A (ja) * 2005-02-14 2008-08-07 ザイモジェネティクス，インコーポレイティド 皮膚リンパ球抗原陽性細胞により仲介される疾患を治療するための方法
US20130109629A1 (en) * 2010-06-28 2013-05-02 Universitätsklinikum Freiburg Blockade of ccl18 signaling via ccr6 as a therapeutic option in fibrotic diseases and cancer
US9726666B2 (en) * 2011-06-13 2017-08-08 Tla Targeted Immunotherapies Ab Diagnosing and treating inflammatory diseases
US20150337037A1 (en) * 2012-06-05 2015-11-26 Msm Protein Technologies Human monoclonal antibodies against human chemokine receptor ccr6
MA41480A (fr) * 2014-10-17 2017-12-19 Glenmark Pharmaceuticals Sa Anticorps qui se lient au ccr6 et leurs utilisations
CN116059203A (zh) * 2015-05-27 2023-05-05 赛博治疗有限责任公司 自分泌运动因子抑制剂及其用途
CN105998015A (zh) * 2016-05-23 2016-10-12 中国人民解放军第二军医大学 PPARδ选择性拮抗剂在制备治疗银屑病药物中的应用
CN106728702A (zh) * 2017-02-20 2017-05-31 高增强 一种预防银屑病复发的药剂

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002026764A2 (fr) * 2000-09-26 2002-04-04 Genaissance Pharmaceuticals, Inc. Haplotypes du gene ccr6
CN103588697A (zh) * 2012-08-14 2014-02-19 中国科学院上海药物研究所 一类2，5-二取代苯磺酰胺类化合物及其制备方法和用途
WO2015084842A1 (fr) * 2013-12-02 2015-06-11 Chemocentryx, Inc. Composés ccr6
WO2017087607A1 (fr) * 2015-11-19 2017-05-26 Chemocentryx, Inc. Modulateurs des récepteurs des chimiokines
WO2019136370A2 (fr) * 2018-01-08 2019-07-11 Chemocentryx, Inc. Méthodes de traitement du psoriasis pustuleux généralisé avec un antagoniste de ccr6 ou cxcr2

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
IRÈNE GALLAIS SÉRÉZAL, HOFFER ELENA, IGNATOV BORISLAV, MARTINI ELISA, ZITTI BEATRICE, EHRSTRÖM MARCUS, EIDSMO LIV: "A skewed pool of resident T cells triggers psoriasis-associated tissue responses in never-lesional skin from patients with psoriasis", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 143, no. 4, 13 August 2018 (2018-08-13), pages 1444 - 1454, XP055771746, ISSN: 0091-6749, DOI: 10.1016/j.jaci.2018.08.048 *
SAMBROOK ET AL.: "Molecular Cloning: Laboratory Guide", 1989, COLD SPRING HARBOR LABORATORY PRESS
See also references of EP4026561A4

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4223289A1 (fr) * 2022-02-07 2023-08-09 Liangdan Sun Application de préparation pour inhiber l'expression camk2g dans la préparation d'un médicament pour le traitement du psoriasis

Also Published As

Publication number Publication date
EP4026561A1 (fr) 2022-07-13
CN112190708A (zh) 2021-01-08
EP4026561A4 (fr) 2023-11-15
CN117018202A (zh) 2023-11-10
CN112190708B (zh) 2023-09-05
US20220401459A1 (en) 2022-12-22

Similar Documents

Publication Publication Date Title
Lacroix et al. The bacterial endotoxin lipopolysaccharide has the ability to target the brain in upregulating its membrane CD14 receptor within specific cellular populations
Nguyen et al. Chronic exposure to beta-blockers attenuates inflammation and mucin content in a murine asthma model
Spadaro et al. Intracerebroventricular administration of interleukin-1 to mice alters investigation of stimuli in a novel environment
Liu et al. Diabetes alters the response to bacteria by enhancing fibroblast apoptosis
JP6837486B2 (ja) 加齢に関連する認知障害及び神経炎症を予防及び／又は治療する方法
CN107427502B (zh) 使用川地匹坦的治疗方法
Xue et al. The role of dendritic cells regulated by HMGB1/TLR4 signalling pathway in myocardial ischaemia reperfusion injury
Oyamada et al. The role of mineralocorticoid receptor expression in brain remodeling after cerebral ischemia
US7192941B2 (en) Estradiol metabolites for the treatment of pulmonary hypertension
JP2015500820A (ja) Ｅｇｆｒ阻害の有害反応を予防または処置するための組成物
WO2021004229A1 (fr) Nouvelle application de l'inhibiteur du récepteur de chimiokine ccr6 dans la prévention de la récurrence du psoriasis
EP3137084B1 (fr) Amiloride de benzyle pour le traitement du psoriasis
RU2712281C1 (ru) Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма
JP2019537615A (ja) シェーグレン症候群の治療におけるペオニフロリン−６’−ｏ−ベンゼンスルホン酸の使用
WO2005102309A2 (fr) Liberation in vivo de mediateurs endogenes antimicrobiens par administration de leukotriene b4 (ltb4)
JP2021510159A (ja) セルドゥラチニブ含有局所皮膚医薬組成物およびその使用
JPH05501716A (ja) γインターフエロンによるアトピー性疾患の処置
DE102017215154A1 (de) Zusammensetzung zur topischen Behandlung von nicht-Mikroorganismus-verursachten entzündlichen Haut- und Schleimhauterkrankungen
ES2932076T3 (es) Moduladores agonistas de los receptores de glucocorticoides selectivos (SEGRAM) no esteroideos y usos de los mismos
WO2023202439A1 (fr) Utilisation der dérivé de composé diterpène ou de sel de celui-ci dans la préparation de médicament pour prévention et traitement d'une dermatite atopique
WO2024029597A1 (fr) REMÈDE POUR L'ŒIL SEC CONTENANT UN OLIGONUCLÉOTIDE D'ADN SE LIANT SÉLECTIVEMENT À L'IFN-γ
JP7382625B2 (ja) 掻痒治療剤
WO2024222207A1 (fr) Utilisation d'un inhibiteur de transport de protéines dans la préparation d'un médicament pour le traitement de la résorption osseuse inflammatoire
Gherbon et al. Improvement Of Graves’ Ophthalmopathy After Administration Of The Cyclooxygenase-2 Selective Inhibitor Celecoxib: A Case-Report
US10438128B2 (en) Treatment of autoimmune and inflammatory diseases with the arsenic compounds AS2O3 and/or AS2O5 administered locally

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20837486

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2020837486

Country of ref document: EP

Effective date: 20220208